Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
Key Highlights
- ➤Three-year follow-up: all patients maintained responses with no tumor progression
- ➤Two-year data showed 75% Objective Response Rate and 25% complete responses
- ➤Six of 12 responders continued into one-year extension receiving EVX-01 monotherapy
- ➤EVX-01 induced immune responses in all patients; 86% neoantigens generated potent T-cell responses
Expert Statements
Birgitte Rønø, CSO and COO of Evaxion
“We are highly excited by the new data reflecting a long durability of clinical responses in this hard-to-treat patient population. This is another strong confirmation of the clinical potential of personalized cancer vaccines in general, and EVX-01 in particular, which we are looking forward to sharing and discussing at the important ESMO Congress. The new data further adds to EVX-01’s strong data package as a good foundation for potential partnership discussions”
* Three-year data from the EVX-01 phase 2 trial in patients with advanced melanoma to be presented at the ESMO 2026 Congress * Data supplements unprecedented two-year data from the trial including a 75% Objective Response Rate with 25% of patients obtaining a complete response * This new clinical and new immune data will be presented at a poster session on October 24, 2026, followed by a webinar on October 29, 2026, providing further insights into the findings COPENHAGEN, Denmark, October 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces new three-year clinical outcome data for personalized cancer vaccine EVX-01 in patients with advanced melanoma.
All patients at three-year follow-up in the phase 2 trial maintained the clinical responses observed at two-year follow-up, with no tumor progression observed. In the third year of treatment, patients received EVX-01 as stand-alone therapy. The data, coupled with new immune data, will be presented in a poster session at the European Society for Medical Oncology (ESMO) Congress 2026 to be held in Madrid, Spain, from October 23-27, 2026.
Get started
Create a free account to read the full story.